Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HIV gp120 vaccine - VaxGen

Drug Profile

HIV gp120 vaccine - VaxGen

Alternative Names: AIDSVAX; AIDSVAX B/B'; AIDSVAX B/E; HIV gp120 vaccine - Genentech; HIV gp120 vaccine AIDSVAX - VaxGen; HIV vaccine AIDSVAX - VaxGen

Latest Information Update: 28 Jan 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genentech; VaxGen
  • Developer Centre Hospitalier Universitaire Vaudois; EuroVacc Foundation; Global Solutions for Infectious Diseases; International AIDS Vaccine Initiative; MRC/UVRI Uganda Research Unit on AIDS; VaxGen
  • Class AIDS vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported HIV-1 infections

Most Recent Events

  • 07 Aug 2018 National Institute of Allergy and Infectious Diseases plans a phase I trial for HIV Infections in October 2018 (NCT03618056)
  • 28 Jan 2018 No recent reports of development identified for phase-I development in HIV-1-infections(Combination therapy, Prevention) in Uganda (IM, Injection)
  • 15 Mar 2017 EuroVacc Foundation initiates enrolment in the EV07 phase I trial for HIV-I infections (Prevention) in Uganda (NCT03391375)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top